双语新闻：研究人员重新研究阿尔茨海默病疫苗
Researchers are renewing efforts to find Alzheimer's disease treatments that remove harmful proteins from the brain. Such vaccines could possibly offer an easier and lower-cost choice for millions of people, several scientists and industry leaders say.
研究人员正在重新努力寻找阿尔茨海默病的治疗方法，从大脑中去除有害蛋白质。一些科学家和行业领袖说，这种疫苗可能为数百万人提供一种更简单、成本更低的选择。
The brain-wasting disease causes thinking and memory problems.
这种脑萎缩疾病会导致思维和记忆问题。
The U.S. government website ClinicalTrials.gov shows that at least seven possible Alzheimer's vaccines are in human testing or have completed such trials. The experimental treatments are designed to use the body's natural defense system to destroy Alzheimer's-linked proteins in the brain. The proteins are beta amyloid and tau.
美国政府网站ClinicalTrials.gov显示，至少有七种可能的阿尔茨海默病疫苗正在进行人体试验或已经完成此类试验。这种实验性疗法旨在利用人体的自然防御系统来破坏大脑中与阿尔茨海默氏症相关的蛋白质。这些蛋白质是-淀粉样蛋白和tau蛋白。
The renewed interest in Alzheimer's vaccines follows a promising first attempt more than 20 years ago. That vaccine work halted after six percent of study volunteers developed a life-threatening brain condition called meningoencephalitis.
对阿尔茨海默氏症疫苗的重新关注是在20多年前第一次有希望的尝试之后。在6%的研究志愿者患上了一种威胁生命的脑部疾病——脑膜脑炎后，疫苗工作停止了。
Researchers then found a safer method using closely targeted synthetic antibodies in patients. These antibodies avoid extreme immune system reaction.
研究人员随后发现了一种更安全的方法，即在患者体内使用紧密靶向的合成抗体。这些抗体避免了极端的免疫系统反应。
Health care companies Eisai and Biogen launched a new medication called Leqembi and health care company Eli Lilly launched Donanemab. American government drug experts are reviewing the treatments.
医疗保健公司卫材和百健推出了一种名为Leqembi的新药，医疗保健公司礼来推出了Donanemab。美国政府药物专家正在审查这些治疗方法。
The reported success of the drugs has strengthened the theories that amyloid removal is critical to fighting Alzheimer's.
据报道，这些药物的成功强化了淀粉样蛋白去除对对抗阿尔茨海默氏症至关重要的理论。
Scientists believe they now understand what went wrong with the first vaccine. They are testing shots they hope will cause an immune reaction without causing too much inflammation.
科学家们相信，他们现在明白了第一种疫苗的问题所在。他们正在测试疫苗，希望能在不引起太多炎症的情况下引起免疫反应。
Dr. Reisa Sperling is an Alzheimer's researcher at Mass General Brigham in Boston. She said she believes vaccines will play an important part as researchers look to prevent Alzheimer's. She said, "I'm very keen that that's where we need to go."
Reisa Sperling博士是波士顿布里格姆总医院的阿尔茨海默病研究员。她说，她相信疫苗将在研究人员寻求预防阿尔茨海默氏症的过程中发挥重要作用。她说:“我非常希望这是我们需要去的地方。”
Sperling is leading a trial in people with Alzheimer's proteins in their brains but showing no signs of related problems. She is considering vaccines for her next study in people who have Alzheimer's proteins in their blood, but not enough to show on imaging of the brain.
斯珀林正在领导一项针对大脑中含有阿尔茨海默氏症蛋白质但没有显示出相关问题迹象的人的试验。她正在考虑为她的下一项研究接种疫苗，研究对象是血液中含有阿尔茨海默氏症蛋白质，但不足以在大脑成像上显示出来的人。
Alzheimer's vaccines are still in the early stages and will require large, years-long trials to show they work.
阿尔茨海默氏症疫苗仍处于早期阶段，需要长达数年的大规模试验才能证明其有效性。
But a vaccine given two or four times a year could offer a lower-cost solution than Leqembi. Leqembi is given twice a month. That could expand available treatment among the estimated 39 million people around the world with Alzheimer's.
但是，每年接种两到四次疫苗可以提供比Leqembi更低成本的解决方案。Leqembi每月服用两次。这可能会扩大全球约3900万阿尔茨海默病患者的可用治疗。
Dr. Walter Koroshetz is director of the part of U.S. National Institutes of Health that deals with disorders involving the brain. He said of the vaccines, "They could be worldwide, and not that expensive."
Walter Koroshetz博士是美国国立卫生研究院负责大脑疾病的部门主任。他谈到疫苗时说，“它们可以在全世界推广，而且不那么昂贵。”
研究人员正在重新努力寻找阿尔茨海默病的治疗方法，从大脑中去除有害蛋白质。一些科学家和行业领袖说，这种疫苗可能为数百万人提供一种更简单、成本更低的选择。
The brain-wasting disease causes thinking and memory problems.
这种脑萎缩疾病会导致思维和记忆问题。
The U.S. government website ClinicalTrials.gov shows that at least seven possible Alzheimer's vaccines are in human testing or have completed such trials. The experimental treatments are designed to use the body's natural defense system to destroy Alzheimer's-linked proteins in the brain. The proteins are beta amyloid and tau.
美国政府网站ClinicalTrials.gov显示，至少有七种可能的阿尔茨海默病疫苗正在进行人体试验或已经完成此类试验。这种实验性疗法旨在利用人体的自然防御系统来破坏大脑中与阿尔茨海默氏症相关的蛋白质。这些蛋白质是-淀粉样蛋白和tau蛋白。
The renewed interest in Alzheimer's vaccines follows a promising first attempt more than 20 years ago. That vaccine work halted after six percent of study volunteers developed a life-threatening brain condition called meningoencephalitis.
对阿尔茨海默氏症疫苗的重新关注是在20多年前第一次有希望的尝试之后。在6%的研究志愿者患上了一种威胁生命的脑部疾病——脑膜脑炎后，疫苗工作停止了。
Researchers then found a safer method using closely targeted synthetic antibodies in patients. These antibodies avoid extreme immune system reaction.
研究人员随后发现了一种更安全的方法，即在患者体内使用紧密靶向的合成抗体。这些抗体避免了极端的免疫系统反应。
Health care companies Eisai and Biogen launched a new medication called Leqembi and health care company Eli Lilly launched Donanemab. American government drug experts are reviewing the treatments.
医疗保健公司卫材和百健推出了一种名为Leqembi的新药，医疗保健公司礼来推出了Donanemab。美国政府药物专家正在审查这些治疗方法。
The reported success of the drugs has strengthened the theories that amyloid removal is critical to fighting Alzheimer's.
据报道，这些药物的成功强化了淀粉样蛋白去除对对抗阿尔茨海默氏症至关重要的理论。
Scientists believe they now understand what went wrong with the first vaccine. They are testing shots they hope will cause an immune reaction without causing too much inflammation.
科学家们相信，他们现在明白了第一种疫苗的问题所在。他们正在测试疫苗，希望能在不引起太多炎症的情况下引起免疫反应。
Dr. Reisa Sperling is an Alzheimer's researcher at Mass General Brigham in Boston. She said she believes vaccines will play an important part as researchers look to prevent Alzheimer's. She said, "I'm very keen that that's where we need to go."
Reisa Sperling博士是波士顿布里格姆总医院的阿尔茨海默病研究员。她说，她相信疫苗将在研究人员寻求预防阿尔茨海默氏症的过程中发挥重要作用。她说:“我非常希望这是我们需要去的地方。”
Sperling is leading a trial in people with Alzheimer's proteins in their brains but showing no signs of related problems. She is considering vaccines for her next study in people who have Alzheimer's proteins in their blood, but not enough to show on imaging of the brain.
斯珀林正在领导一项针对大脑中含有阿尔茨海默氏症蛋白质但没有显示出相关问题迹象的人的试验。她正在考虑为她的下一项研究接种疫苗，研究对象是血液中含有阿尔茨海默氏症蛋白质，但不足以在大脑成像上显示出来的人。
Alzheimer's vaccines are still in the early stages and will require large, years-long trials to show they work.
阿尔茨海默氏症疫苗仍处于早期阶段，需要长达数年的大规模试验才能证明其有效性。
But a vaccine given two or four times a year could offer a lower-cost solution than Leqembi. Leqembi is given twice a month. That could expand available treatment among the estimated 39 million people around the world with Alzheimer's.
但是，每年接种两到四次疫苗可以提供比Leqembi更低成本的解决方案。Leqembi每月服用两次。这可能会扩大全球约3900万阿尔茨海默病患者的可用治疗。
Dr. Walter Koroshetz is director of the part of U.S. National Institutes of Health that deals with disorders involving the brain. He said of the vaccines, "They could be worldwide, and not that expensive."
Walter Koroshetz博士是美国国立卫生研究院负责大脑疾病的部门主任。他谈到疫苗时说，“它们可以在全世界推广，而且不那么昂贵。”
